Department of Rehabilitation Medicine of First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
The School of Health, Fujian Medical University, Fuzhou, 350122, China.
Cerebellum. 2024 Aug;23(4):1713-1717. doi: 10.1007/s12311-023-01637-y. Epub 2023 Nov 22.
Ataxia-ocular apraxia 2 (AOA2) is a rare neurodegenerative autosomal recessive disorder with no effective treatment. In this study, we present the case of a patient diagnosed with AOA2, who experienced walking instability and uncoordinated movement. The patient underwent transcranial alternating current stimulation (tACS) treatment for 4 weeks with follow-up after 1 month. The effectiveness of the treatment was evaluated using the International Cooperative Ataxia Rating Scale (ICARS), the Scale for the Assessment and Rating of Ataxia (SARA), the 9-Hole Peg Test (9HPT), and functional near-infrared spectroscopy (fNIRS). Following treatment, the patient's ataxia symptoms showed significant improvement and continued to be alleviated during the follow-up period, suggesting a lasting effect of tACS treatment. Our findings from this case study provide compelling evidence for the potential of tACS as a treatment option for AOA2.
眼动性共济失调-动作不能 2 型(AOA2)是一种罕见的神经退行性常染色体隐性遗传病,目前尚无有效的治疗方法。本研究报道了 1 例 AOA2 患者,该患者出现行走不稳和运动不协调。对该患者进行了为期 4 周的经颅交流电刺激(tACS)治疗,并在 1 个月后进行了随访。采用国际合作共济失调评分量表(ICARS)、共济失调评定量表(SARA)、九孔钉测试(9HPT)和功能性近红外光谱(fNIRS)评估治疗效果。治疗后,患者的共济失调症状显著改善,在随访期间持续缓解,提示 tACS 治疗具有持久效果。本病例研究结果为 tACS 作为 AOA2 治疗选择的潜力提供了有力证据。